Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

The Lancet. Oncology - 1 Mar 2020

Schmid Sabine, Früh Martin, Peters Solange

Abstract excerpt

No abstract is available from the source.

Topics

Acrylamides
Aniline Compounds
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Pyrazines
Triazines

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32027845
DOI: 10.1016/S1470-2045(19)30859-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?PMID 32027845Read ↗

EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?Semantic proximity Read ↗

Epidermal Growth Factor Receptor targeting in non-small cell lung cancer: revisiting different strategies against the same target.Semantic proximity Read ↗

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Semantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

Molecular therapeutic targets in non-small cell lung cancer.Semantic proximity Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.